Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Drop in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 500 shares, a drop of 99.2% from the October 31st total of 65,600 shares. Based on an average trading volume of 595,800 shares, the days-to-cover ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Up 7.1 %

Shares of PVCT stock traded up $0.01 during mid-day trading on Thursday, hitting $0.12. 443,642 shares of the stock traded hands, compared to its average volume of 251,178. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.22. The company’s 50-day simple moving average is $0.11 and its 200-day simple moving average is $0.12.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.